Healthscope agrees to sell Asian pathology operations for $279m

Company News

by Anna Napoli

Healthscope (ASX:HSO) has agreed to sell its Asian pathology operations in Singapore, Malaysia and Vietnam for $279 million to private equity firm TPG Capital Asia.

The private healthcare provider expects to book a gain on sale of around $165 million. Proceeds of the sale will be used to pay down debt and fund Healthscope’s expansion pipeline.

The Asian pathology operations contributed earnings (EBITDA) of $18.2 million in Financial Year 17 and $9.6 million in the first half of 2018.

Healthscope MD and CEO, Gordon Ballantyne says the outcome realises significant value for Healthscope shareholders following a tough and competitive sales process.

Shares in Healthscope (ASX:HSO) are trading down 0.67 per cent to $2.21.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.